391 related articles for article (PubMed ID: 25630411)
21. Colistin: understanding and applying recent pharmacokinetic advances.
Ortwine JK; Kaye KS; Li J; Pogue JM
Pharmacotherapy; 2015 Jan; 35(1):11-6. PubMed ID: 25187500
[TBL] [Abstract][Full Text] [Related]
22. Colistin in critically ill patients.
Boisson M; Gregoire N; Couet W; Mimoz O
Minerva Anestesiol; 2013 Feb; 79(2):200-8. PubMed ID: 23241733
[TBL] [Abstract][Full Text] [Related]
23. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.
Pogue JM; Ortwine JK; Kaye KS
Clin Microbiol Infect; 2017 Apr; 23(4):229-233. PubMed ID: 28238870
[TBL] [Abstract][Full Text] [Related]
24. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
25. [Shedding light on the use of colistin: still gaps to be filled].
Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
[TBL] [Abstract][Full Text] [Related]
26. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
Gales AC; Reis AO; Jones RN
J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
[TBL] [Abstract][Full Text] [Related]
27. Optimizing use of colistin and polymyxin B in the critically ill.
Nation RL; Li J
Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224
[TBL] [Abstract][Full Text] [Related]
28. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
Falagas ME; Kasiakou SK
Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
[TBL] [Abstract][Full Text] [Related]
29. Intravenous polymyxins: Revival with puzzle.
Yu Y; Fei A; Wu Z; Gao C; Pan S
Biosci Trends; 2017; 11(4):370-382. PubMed ID: 28904326
[TBL] [Abstract][Full Text] [Related]
30. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
31. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
32. Colistin and polymyxin B: peas in a pod, or chalk and cheese?
Nation RL; Velkov T; Li J
Clin Infect Dis; 2014 Jul; 59(1):88-94. PubMed ID: 24700659
[TBL] [Abstract][Full Text] [Related]
33. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
34. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
Gales AC; Jones RN; Sader HS
J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
[TBL] [Abstract][Full Text] [Related]
35. Clinical Use of Polymyxin B.
Rigatto MH; Falci DR; Zavascki AP
Adv Exp Med Biol; 2019; 1145():197-218. PubMed ID: 31364080
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections.
Kwa AL; Lim TP; Low JG; Hou J; Kurup A; Prince RA; Tam VH
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):163-7. PubMed ID: 17916420
[TBL] [Abstract][Full Text] [Related]
37. Adverse reactions associated with systemic polymyxin therapy.
Justo JA; Bosso JA
Pharmacotherapy; 2015 Jan; 35(1):28-33. PubMed ID: 25266910
[TBL] [Abstract][Full Text] [Related]
38. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
Zavascki AP; Nation RL
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
[TBL] [Abstract][Full Text] [Related]
39. New information about the polymyxin/colistin class of antibiotics.
Molina J; Cordero E; Pachón J
Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
[TBL] [Abstract][Full Text] [Related]
40. Polymyxins: a new hope in combating Gram-negative superbugs?
Velkov T; Roberts KD; Thompson PE; Li J
Future Med Chem; 2016 Jun; 8(10):1017-25. PubMed ID: 27328129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
